Work

Pretreatment CT-based clinical deep learning radiomics model for predicting the response of hepatocellular carcinoma patients with portal vein thrombosis treated with TKIs plus PD-1 inhibitors and hepatic arterial infusion chemotherapy

Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Background This study aimed to construct a pretreatment contrast-enhanced CT (CECT)-based multimodal model for noninvasive forecasting of early treatment response in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) who received hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and PD-1 inhibitors (HTI). Methods We retrospectively enrolled 116 patients with HCC and PVTT receiving HTIs (2019–2024), randomly divided 7:3 into training (n = 81) and test (n = 35) cohorts. Early objective response was assessed 6–8 weeks after treatment using modified RECIST. Radiomic features were extracted from three-dimensional volumes of interest of the primary tumor and PVTT; deep features from the largest axial tumor slice using ResNet101. Six models were developed; the final radiomic–deep learning–clinical (RCLD) model integrated out-of-fold component probabilities. Discrimination, calibration, clinical utility, and overall survival (OS) stratification were evaluated. Results Sixty-eight patients responded (complete response, n = 3; partial response, n = 65); the objective response rate was 58.6% and disease control rate 91.4%. Four radiomic and three deep learning features were selected; cirrhosis was the only clinical variable. RCLD achieved the highest AUC (training 0.965, 95% CI 0.929–1.000; test 0.924, 95% CI 0.822–1.000). In the test cohort, RCLD outperformed clinical-only and radiomics–clinical models ( p = 0.003 and p = 0.026), with no significant differences from other imaging-based models. RCLD stratified OS (training P = 0.003; test P = 0.027). Conclusion A pretreatment CECT-based multimodal model integrating radiomics, deep learning, and cirrhosis predicted early objective response and stratified OS risk in HCC with PVTT receiving HTIs. Prospective multicenter validation is required.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7236580782
Cites: 32
Cited by:
Related to: 10